(Date:11/21/2008)...But researchers remain cautious about future antib..., FRIDAY, Nov. 21 (HealthDay News) -- People with...disease (COPD) may be able to reduce the frequency... common antibiotic, a new report says. , The s... the American Journal of Respiratory and Critical...
(Date:11/21/2008)...MORGANTOWN, W.Va., Nov. 21 /PRNewswire-USNewswire/...examining whether a smokeless, spitless tobacco pr...e researchers have found that RJ Reynolds, Camel S...fy addiction - contains surprisingly high levels o...icotine than most other snuff products," said Bruc...
(Date:11/21/2008)...NEW YORK, Nov. 21 The general memb...ted to induct three new individuals at their Annua...he Pierre hotel in New York. A,Lifetime Achieveme...uctees into the Medical Advertising Hall of Fame a...g career with an account position,at Sudler &...
(Date:11/21/2008)...Experiments in mice find running increases product.... 21 (HealthDay News) -- In experiments in mice, e...uction of brain stem cells usually seen with aging...le restoration of the brain,s ability to stave off...restore a neurochemical that is essential for the ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Exercise Keeps the Brain Young 2(Date:11/20/2008)...ASHINGTON, Nov. 20 The ...amp; Gender Equity: , , WHAT: World AIDS ... Tuesday, November 25, 2008 , 11:00 a.m. EST ...ngly encouraged: https://cc.readytalk.com/r/1xe41...s outpacing the number of people newly put on trea...
(Date:11/20/2008)..., , , , PHILADELPHIA, Nov. 20 /PRNe... today announced that the United States Food and D...val for PROMACTA(R) (eltrombopag) for the treatmen...une (idiopathic) thrombocytopenic purpura (ITP) wh...oids, immunoglobulins or splenectomy. The approval...
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswire-F...hat the Anti-infective Drugs Advisory Committee of...voted 17 to 2 against the,approval of intravenous...for,the treatment of patients with complicated sk...ing those caused by methicillin-resistant Staphylo...
(Date:11/20/2008)...MERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ ...company will present results from the Phase 1B,cl...nced metastatic breast,cancer, BZL101, at the Soc...l,Conference in Atlanta, Georgia. The Company,s ...bstract and will be presented as a part of the Bes...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21 11583 1Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21 11583 2MIT develops thin film micro pharmacy 11580 1MIT develops thin film micro pharmacy 11580 2Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 11575 1Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 11575 2Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 11575 3Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 1Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 2Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 3Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 4Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 5Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 6Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 7Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 8Hanger Orthopedic Group Inc Announces an 11 25 Sales Increase and a 35 25 Increase in EPS to 240 23 for the Quarter Ended December 31 2007 Compar 11570 9...ebivolol Lowers Blood Pressure in Obese and,Non-Ob...PRNewswire-FirstCall/ -- Forest,Laboratories, Inc....tudies and one pooled analysis of nebivolol, a sel... currently under review by,the U.S. Food and Drug ...sion. Data from the two clinical studies show that...
...sented today at Digestive Disease Week -, CAMBRIDG...day,announced the presentation of data from a Phas... transit and improved bowel function,in patients w...rome,(IBS-C). These data also showed linaclotide w...events. Linaclotide is a first-in-class,compound c...
Other Medicine Technology:Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: